Pre-made Aselizumab benchmark antibody (Whole mAb, anti-SELL therapeutic antibody, Anti-CD62L/LAM1/LECAM1/LEU8/LNHR/LSEL/LYAM1/PLNHR/TQ1 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-INN-739

Anti-SELL therapeutic antibody (Pre-made Aselizumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Aselizumab is an immunosuppressive drug which has been investigated for the use in severely injured patients. It binds to CD62L.[1]

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-INN-739-1mg 1mg 3090
GMP-Bios-INN-739-10mg 10mg Inquiry
GMP-Bios-INN-739-100mg 100mg Inquiry
GMP-Bios-INN-739-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Aselizumab Biosimilar, Whole Mab, Anti-Sell Antibody: Anti-CD62L/LAM1/LECAM1/LEU8/LNHR/LSEL/LYAM1/PLNHR/TQ1 therapeutic antibody
INN Name Aselizumab
TargetSELL
FormatWhole mAb
DerivationHumanized
Species Reactivityhuman
CH1 IsotypeIgG4 - nd
VD LCIgG4 - nd
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies0
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech0